Pierre Rodriguez Alarcon
Hematology & Oncology · Chicago, ILNPI 1770100596
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,090 of the $3,676 with a category attached, or 84.1%. It is spread thinly across 25 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,989, 5.7 times the $347 reported in 2023.
Across 77 payments — averaging $47.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adaptive Biotechnologies Corporation$810
- Sobi, Inc$317
- Lilly USA, LLC$312
- Incyte Corporation$262
- AstraZeneca$240
- Gilead$234
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,09084%
- Education$58616%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adaptive Biotechnologies Corporation | 8 | $810 |
| Sobi, Inc | 5 | $317 |
| Lilly USA, LLC | 10 | $312 |
| Incyte Corporation | 4 | $262 |
| AstraZeneca(2 entities) | 6 | $240 |
| Gilead(2 entities) | 4 | $234 |
| Springworks Therapeutics, Inc. | 4 | $221 |
| Genentech USA, Inc. | 7 | $191 |
| Daiichi Sankyo Inc. | 4 | $170 |
| Syndax Pharmaceuticals, Inc. | 1 | $130 |
| Pfizer | 4 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $110 |
| Astellas Pharma US Inc | 1 | $100 |
| Bayer | 4 | $93 |
| Sanofi | 2 | $76 |
| Mirati Therapeutics, Inc. | 2 | $54 |
| Deciphera Pharmaceuticals Inc. | 1 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Amgen | 1 | $31 |
| GSK | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| EMD Serono, Inc. | 1 | $21 |
| Pharmaand GmbH | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,676 in reported general payments places this provider in the 55th percentile of 580 hematology & oncology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 21 | $283,734 |
| XtandiEnzalutamide | 17 | $244,830 |
| PromactaEltrombopag Olamine | 11 | $147,137 |
| InqoviDecitabine/Cedazuridine | 12 | $101,121 |
| Hydroxyurea | 14 | $204 |
| Acyclovir | 21 | $174 |
| Prednisone | 19 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $100 | $244,83017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.